Form 4: Altimmune CFO Granted Equity Awards

Altimmune's Chief Financial Officer, Gregory L. Weaver, was granted 166,800 stock options and 57,900 Restricted Stock Units, vesting over four years.

Summary

• Gregory L. Weaver, Chief Financial Officer of Altimmune, Inc. (ALT), acquired derivative securities on October 1, 2025.
• The acquisition included 166,800 stock options with an exercise price of $3.87 per share.
• The stock options vest over four years, with 25% vesting on October 1, 2026, and the remainder vesting in equal monthly installments for the subsequent 36 months.
• The stock options have an expiration date of October 1, 2035.
• Additionally, 57,900 Restricted Stock Units (RSUs) were granted, each representing a contingent right to receive one share of Common Stock.
• The RSUs also vest over four years, with 25% vesting on October 1, 2026, and the remainder vesting in equal annual installments for the following three years.
• Both grants are subject to Mr. Weaver's continued service through the applicable vesting dates.
• Following these transactions, Mr. Weaver beneficially owns 166,800 stock options and 57,900 Restricted Stock Units directly.

Sentiment

Score: 6

Explanation: The filing reflects a standard executive compensation event, which is generally positive for aligning management incentives with shareholder interests but does not indicate new operational or financial performance.

Positives

• The equity grants align the Chief Financial Officer's interests with those of shareholders, incentivizing long-term performance and retention.
• The vesting schedule encourages continued service and commitment from a key executive over a four-year period.

Risks

• The value of the stock options and RSUs is subject to the future performance of Altimmune's common stock, meaning the awards may not realize their full potential value if the stock price declines.
• Vesting is contingent on continued service, posing a risk of forfeiture if the reporting person's employment terminates before vesting dates.

Future Outlook

The equity awards are structured to incentivize the Chief Financial Officer's continued service and contribution to the company's long-term success, with vesting schedules extending over four years.

Industry Context

The granting of stock options and Restricted Stock Units to executive officers is a standard practice in the biotechnology and pharmaceutical industries, aiming to attract, retain, and motivate key talent by aligning their compensation with company performance and shareholder value creation.

Comparison to Industry Standards

• Equity compensation, including stock options and RSUs, is a common component of executive remuneration packages across the biotechnology sector, similar to practices observed at companies like Moderna, BioNTech, or Regeneron Pharmaceuticals, which frequently use such incentives to retain scientific and management talent.
• The four-year vesting schedule is typical for executive equity grants, providing a long-term incentive structure consistent with industry benchmarks for executive retention and performance alignment.

Stakeholder Impact

• Shareholders: The grants align the Chief Financial Officer's financial interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: May signal stability in executive leadership and a commitment to retaining key personnel.

Next Steps

• Continued service by Gregory L. Weaver is required for the vesting of the granted stock options and Restricted Stock Units.

Key Dates

Keywords

Altimmune, ALT, Gregory Weaver, CFO, Stock Options, Restricted Stock Units, RSU, Equity Grant, Executive Compensation, Form 4